Skip to main content

Advertisement

Table 1 Clinical and pathological characteristics of the study cohort

From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

Patients, n = 33 Value
Age (years)  
 Median 70
 Range 53-82
ECOG performance status, n (%)  
 0 23 (69.6)
 1 5 (15.2)
 2 5 (15.2)
Gleason score at diagnosis, n (%)  
 Unknown 3 (9.1)
  ≤ 7 11 (33.3)
  ≥ 8 19 (57.6)
Primary therapy, n (%)  
 RP 9 (27.3)
 EBRT 4 (12.1)
 Palliative 20 (60.6)
Metastatic sites, n (%)  
 Soft tissue 3 (9.0)
 Bone + LN 15 (45.5)
 Bone + Visceral ± LN 15 (45.5)
Biochemical markersa  
 PSA [ng/dl] 140
0.1-3378
 Lactate dehydrogenase [U/l] 320
218-1900
 Alkaline phosphatase [U/l] 164
50-1466
 Hemoglobin [g/dl] 11.6
8.5-16.1
  1. ECOG, eastern cooperative oncology group; EBRT, external beam radiotherapy; LN, lymph node metastases; PSA, prostate-specific antigen; RP, radical prostatectomy; n, number
  2. avalues given as median and range